

# Datasheet

## Recombinant human Leukemia Inhibitory Factor (LIF)

<b>Catalog Number:</b>	PR16101	<b>Product Type:</b>	Recombinant protein
<b>Source:</b>	Recombinant human LIF is expressed in <i>E. coli</i> as a fusion protein with GST using the pGEX expression system, cleaved from GST moiety with thrombin and purified by HPLC chromatography.		
<b>Purity:</b>	Greater than 95% by analytical HPLC and SDS-PAGE. <b>Concentration:</b> 10ug/ml		
<b>Endotoxin Levels:</b>	Endotoxin level is less than 0.1 ng per µg of LIF. Tested negative in both aseptic and microplasmic tests.		
<b>Activity:</b>	The activity of human LIF is determined by the ability to induce differentiation of M1 myeloid leukemic cells. The minimum detectable concentration of human LIF in this assay is 0.5ng/mL. The specific activity is >1 x 10 <sup>8</sup> units/mg, where 50 units is defined as the amount of human LIF required to induce differentiation in 50% of the M1 colonies in 1 mL agar cultures.		
<b>Format:</b>	Liquid in PBS, pH 7.4 and 0.02% Tween 20. No preservatives added.		
<b>Storage:</b>	Maintain at 2-8°C until expiration date. Further dilutions should be made into buffer or medium to which protein (e.g., 1% BSA) or Tween 20 has been added.		

Leukemia Inhibitory Factor (LIF) is a lymphoid factor which promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. LIF has a number of other activities including cholinergic neuron differentiation, control of stem cell pluripotency, bone and fat metabolism, mitogenesis of certain factor dependent cell lines and promotion of megakaryocyte production *in vivo*. Human LIF is a 19.7 kDa protein containing 181 amino acid residues. The non-glycosylated, *E. coli* expressed, recombinant human LIF is indistinguishable from native LIF in its biological activities *in vitro*. Human and murine mature LIF exhibit a 78% sequence identity at the amino acid control. Human LIF is equally active on both human and mouse cells. Murine LIF is approximately 1000 fold less active on human cells, than hLIF.

### REFERENCES:

- Hilton D. and Gough M. (1998). *Cytokines*, chapter 20, 277-288. Academic Press Limited.
- Carpenter M.K., Cui X., Hu Z., Jackson J. *et al* (1999). In vitro expansion of a Multipotent Population of Human Neural Progenitor Cells. *Experimental Neurology* **158**: 265-278.
- Vogiagis D. and Salamonsen L.A. (1999). The role of leukemia inhibitory factor in the establishment of pregnancy. *Journal of Endocrinology* **160**: 181-190.
- Kami K., Morikawa Y., Kawai Y. and Senba E. (1999). Leukemia Inhibitor Factor, Glial cell line derived neurotrophic factor, and their receptor expressions following muscle crush injury. *Muscle & Nerve* **22**: 1576-1586.
- Ren S.G., Seliktar J., Li X., Hershman M. *et al* (1999). In vivo and in vitro regulation of Thyroid Leukemia Inhibitory Factor (LIF): Marker of Hypothyroidism. *J. Clin. Endo. Metab.* **84**: 2883-2887.
- Shih C.C., Hu M.C., Hu J., Weng Y. *et al* (2000). A secreted and LIF-mediated stromal cell-derived activity that promotes ex vivo expansion of human hematopoietic stem cells. *Blood* **95**: 1957-1966.

### RECOMMENDED PROTOCOL

#### M1 Bioassay

- The M1 bioassay is performed using *in vitro* semi-solid agar cultures, which contain approximately 100 cells in 1 mL volumes of DME containing 20 % FCS in 0.3% agar.
- Add 100 µL of sample or hLIF (104 units/mL in 5% FCS in isotonic saline) in two-fold serial dilutions in duplicate to 35 mm petri dishes.
- Add 100 µL of 5% FCS in isotonic saline to two control slides.
- Incubate at 37°C in fully humidified atmosphere of 10% CO<sub>2</sub> in air for 7 days.
- Score the number of colonies that show differentiation (note: 50 units is defined as the amount of activity which results in 50% of the colonies being differentiated).

#### FOR RESEARCH USE ONLY

Neuromics' reagents are for in vitro and certain non-human in vivo experimental use only and not intended for use in any human clinical investigation, diagnosis, prognosis, or treatment. We disclaim all liability in connection with the use of the information contained herein or otherwise, and all such risks are assumed by the user.

phone 866-350-1500 • fax 612-677-3976 • www.neuromics.com

v1